Global Schizophrenia 2016 Market Size, Share Trends, Industry Growth, Analysis And Industry Forecast – Acute Market Reports

General, Healthcare Comments Off on Global Schizophrenia 2016 Market Size, Share Trends, Industry Growth, Analysis And Industry Forecast – Acute Market Reports

Acute Market Reports’s, ‘Schizophrenia – Pipeline Review, H1 2016’, provides an overview of the Schizophrenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects.

Browse Full Report Visit –

Acute Market Reports’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Acute Market Reports’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Browse All Reports of This Category –

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


– The report provides a snapshot of the global therapeutic landscape of Schizophrenia
– The report reviews pipeline therapeutics for Schizophrenia by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Schizophrenia therapeutics and enlists all their major and minor projects
– The report assesses Schizophrenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Schizophrenia

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Schizophrenia
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Get Complete Report @ Schizophrenia – Pipeline Review, H1 2016

Table of Contents 2
Introduction 6
Schizophrenia Overview 7
Therapeutics Development 8
Schizophrenia – Therapeutics under Development by Companies 10
Schizophrenia – Therapeutics under Investigation by Universities/Institutes 17
Schizophrenia – Pipeline Products Glance 18
Schizophrenia – Products under Development by Companies 22
Schizophrenia – Products under Investigation by Universities/Institutes 32
Schizophrenia – Companies Involved in Therapeutics Development 33
Schizophrenia – Therapeutics Assessment 112
Drug Profiles 129
Schizophrenia – Recent Pipeline Updates 329
Schizophrenia – Dormant Projects 387
Schizophrenia – Discontinued Products 402
Schizophrenia – Product Development Milestones 408
Appendix 416

Latest Reports :

Amyotrophic Lateral Sclerosis – Pipeline Review, H1 2016

Relapsed Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H1 2016

Hepatitis B – Pipeline Review, H1 2016
About – Acute Market Reports :

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us : 
Chris Paul
Office No 101, 1st Floor ,
Aditi Mall, Baner,
Pune, MH, 411045
Toll Free(US/CANADA): +1-855-455-8662
India: +91 7755981103
Email :
Website :


Back to Top